JP2016514131A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514131A5 JP2016514131A5 JP2016501052A JP2016501052A JP2016514131A5 JP 2016514131 A5 JP2016514131 A5 JP 2016514131A5 JP 2016501052 A JP2016501052 A JP 2016501052A JP 2016501052 A JP2016501052 A JP 2016501052A JP 2016514131 A5 JP2016514131 A5 JP 2016514131A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- pharmaceutically acceptable
- formula
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000008445 altitude sickness Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 108010016797 Sickle Hemoglobin Proteins 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000001177 diphosphate Chemical group 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical group [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical group NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical class ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- -1 or C 1 -C 6 alkyl Chemical group 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical class [H]O* 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- OMJKVIFSWSQTGQ-UHFFFAOYSA-N 6,7-bis(aziridin-1-yl)quinazoline-5,8-dione Chemical compound C1CN1C=1C(=O)C2=NC=NC=C2C(=O)C=1N1CC1 OMJKVIFSWSQTGQ-UHFFFAOYSA-N 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/815,810 US20140274961A1 (en) | 2013-03-15 | 2013-03-15 | Compounds and uses thereof for the modulation of hemoglobin |
| US13/815,810 | 2013-03-15 | ||
| US14/010,455 | 2013-08-26 | ||
| US14/010,455 US20150057251A1 (en) | 2013-08-26 | 2013-08-26 | Compounds and uses thereof for the modulation of hemoglobin |
| PCT/US2014/022742 WO2014150261A1 (en) | 2013-03-15 | 2014-03-10 | Compounds and uses thereof for the modulaton of hemoglobin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514131A JP2016514131A (ja) | 2016-05-19 |
| JP2016514131A5 true JP2016514131A5 (enExample) | 2017-04-13 |
| JP6355711B2 JP6355711B2 (ja) | 2018-07-11 |
Family
ID=51580730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501052A Active JP6355711B2 (ja) | 2013-03-15 | 2014-03-10 | ヘモグロビンの修飾のための化合物及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2970184B1 (enExample) |
| JP (1) | JP6355711B2 (enExample) |
| CA (1) | CA2902874C (enExample) |
| ES (1) | ES2710380T3 (enExample) |
| TW (1) | TWI630201B (enExample) |
| WO (1) | WO2014150261A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| SMT201700483T1 (it) | 2011-12-28 | 2017-11-15 | Global Blood Therapeutics Inc | Composti benzaldeide sostituiti e metodi per il loro uso nell’aumento dell’ossigenazione tissutale |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| BR112015021986A2 (pt) | 2013-03-15 | 2017-07-18 | Global Blood Therapeutics Inc | compostos e seus usos para a modulação de hemoglobina |
| US9981939B2 (en) | 2013-03-15 | 2018-05-29 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| PE20161035A1 (es) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| JP6809681B2 (ja) | 2014-02-07 | 2021-01-06 | グローバル ブラッド セラピューティクス インコーポレイテッド | ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形 |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| ES3039236T3 (en) | 2015-12-04 | 2025-10-20 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| US10787430B2 (en) | 2016-06-17 | 2020-09-29 | Fronthera U.S. Pharmaceuticals Llc | Hemoglobin modifier compounds and uses thereof |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
| EP3898618A1 (en) * | 2018-12-21 | 2021-10-27 | Crystal Pharma, S.A.U. | Process and intermediates for the preparation of voxelotor |
| WO2021046815A1 (zh) | 2019-09-12 | 2021-03-18 | 凯莱英医药化学（阜新）技术有限公司 | 一种连续化制备2,6-二羟基苯甲醛的装置及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK160866C (da) * | 1980-12-18 | 1991-10-14 | Wellcome Found | Analogifremgangsmaade til fremstilling af phenoletherforbindelser |
| MXPA01011502A (es) | 1999-05-14 | 2003-08-20 | Boehringer Ingelheim Pharma | Compuestos de tipo profarmaco anti-tumorigenos, activados por enzimas. |
| PT2179987E (pt) * | 2002-12-04 | 2013-03-11 | Univ Virginia Commonwealth | Utilização de derivados carbaldeído heterocíclicos contra a anemia falciforme |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| EP2314576A1 (en) * | 2003-11-05 | 2011-04-27 | F.Hoffmann-La Roche Ag | Phenyl derivatives as PPAR agonists |
| TWI407960B (zh) * | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| SMT201700483T1 (it) * | 2011-12-28 | 2017-11-15 | Global Blood Therapeutics Inc | Composti benzaldeide sostituiti e metodi per il loro uso nell’aumento dell’ossigenazione tissutale |
-
2014
- 2014-03-10 EP EP14768759.4A patent/EP2970184B1/en active Active
- 2014-03-10 ES ES14768759T patent/ES2710380T3/es active Active
- 2014-03-10 CA CA2902874A patent/CA2902874C/en active Active
- 2014-03-10 WO PCT/US2014/022742 patent/WO2014150261A1/en not_active Ceased
- 2014-03-10 JP JP2016501052A patent/JP6355711B2/ja active Active
- 2014-03-13 TW TW103109179A patent/TWI630201B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514131A5 (enExample) | ||
| JP2016512823A5 (enExample) | ||
| JP2016516696A5 (enExample) | ||
| KR20200086696A (ko) | 벤조디아제핀-2-온 및 벤조아제핀-2-온 유도체의 분할 방법 | |
| JP2017518959A5 (enExample) | ||
| PH12015500758B1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| JP2019524883A5 (enExample) | ||
| CY1111528T1 (el) | 1-αζα-δικυκλο [3.3.1] εννεανια | |
| JP2016523906A5 (enExample) | ||
| AU2015406100B2 (en) | Novel annelated phenoxyacetamides | |
| KR101774861B1 (ko) | 퓨린 유도체의 사이클로프로판카르복실레이트 에스터 | |
| CN113087712B (zh) | L-氨基酸-6-胶霉毒素酯三氟乙酸盐及其制备方法 | |
| WO2011033307A1 (en) | Nilotinib dihydrochloride salt | |
| SG191841A1 (en) | Methods of making hiv attachment inhibitor prodrug compound and intermediates | |
| CN115175913B (zh) | 取代的双三环化合物及其药物组合物和用途 | |
| JP2022549030A (ja) | 複素環アミド化合物、その薬学的に許容される塩およびその調製方法と使用 | |
| CN115135646B (zh) | 取代的多环化合物及其药物组合物和用途 | |
| CN115894587A (zh) | 一种核苷衍生物的制备及其在抗病毒药物领域中的用途 | |
| CN102212032B (zh) | 一种5-羟基喹诺酮类衍生物及其制备方法和用途 | |
| CN105837632A (zh) | 神经氨酸酶抑制剂及制备方法及在制备抗流感病毒药物中的应用 | |
| CN112079785A (zh) | 一种新型抗流感病毒奥司他韦衍生物、其制备方法及用途 | |
| CN104829669A (zh) | 具有细胞毒活性的2’,5’-双脱氧-5-氟尿嘧啶核苷衍生物、生产方法和应用 | |
| EP2920150B1 (en) | Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters | |
| EP3679030B1 (en) | A process for preparation of triaminopyrimidine compound and intermediates thereof | |
| CN109810063A (zh) | 一种新型抗流感病毒“孪药”、其制备方法及用途 |